Cargando…

Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans

The high morbidity and mortality of cryptococcal meningitis is due to the limited range of therapeutic options: only three classes of antifungal drugs are available (polyenes [amphotericin B], azoles [fluconazole], and pyrimidine analogues [flucytosine]). Fluconazole is the most widely used antifung...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Feng, Gritsenko, Vladimir, Lu, Hui, Zhen, Cheng, Gao, Lu, Berman, Judith, Jiang, Yuan-ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557924/
https://www.ncbi.nlm.nih.gov/pubmed/34585947
http://dx.doi.org/10.1128/Spectrum.00723-21
_version_ 1784592455772930048
author Yang, Feng
Gritsenko, Vladimir
Lu, Hui
Zhen, Cheng
Gao, Lu
Berman, Judith
Jiang, Yuan-ying
author_facet Yang, Feng
Gritsenko, Vladimir
Lu, Hui
Zhen, Cheng
Gao, Lu
Berman, Judith
Jiang, Yuan-ying
author_sort Yang, Feng
collection PubMed
description The high morbidity and mortality of cryptococcal meningitis is due to the limited range of therapeutic options: only three classes of antifungal drugs are available (polyenes [amphotericin B], azoles [fluconazole], and pyrimidine analogues [flucytosine]). Fluconazole is the most widely used antifungal drug in sub-Saharan Africa, where cryptococcal meningitis is a major cause of death in patients infected with HIV. In this study, we found that exposure to fluconazole, even for short times (48 h) at subinhibitory concentrations, drove rapid adaptation of Cryptococcus neoformans serotype A strain H99 via the acquisition of different aneuploid chromosomes. These aneuploidies conferred heteroresistance to fluconazole. Importantly, most of the adaptors were cross-tolerant to flucytosine. Some of the aneuploid adaptors were not heteroresistant to fluconazole but were tolerant to amphotericin B. Thus, exposure to one antifungal drug class can promote adaptation to two antifungal drug classes, highlighting the plasticity of the C. neoformans genome and raising concerns about the rapid reduction in the range of treatment options for cryptococcal infections. IMPORTANCE Cryptococcosis is a globally distributed invasive fungal infection caused by infections with Cryptococcus neoformans or Cryptococcus gattii. Only three classes of therapeutic drugs are clinically available for treating cryptococcosis: polyenes (amphotericin B), azoles (fluconazole), and pyrimidine analogues (flucytosine). Fluconazole is the primary drug available in resource-limited countries. Aneuploidy is a genomic state due to the gain or loss of chromosomes. We found that C. neoformans rapidly adapted to fluconazole by acquiring diverse aneuploidies and that specific aneuploidies enabled improved growth of isolates susceptible (tolerance) to amphotericin B and/or cross-tolerance to both fluconazole and flucytosine. Therefore, aneuploidy is an underlying mechanism of drug tolerance that not only arises rapidly during growth in fluconazole but can also confer tolerance to other antifungal drugs without prior exposure to those drugs. Resistant isolates have high MICs, and all cells grow similarly in medium with the drug, while tolerant isolates test as susceptible and grow slowly at drug concentrations above the MIC.
format Online
Article
Text
id pubmed-8557924
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-85579242021-11-08 Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans Yang, Feng Gritsenko, Vladimir Lu, Hui Zhen, Cheng Gao, Lu Berman, Judith Jiang, Yuan-ying Microbiol Spectr Research Article The high morbidity and mortality of cryptococcal meningitis is due to the limited range of therapeutic options: only three classes of antifungal drugs are available (polyenes [amphotericin B], azoles [fluconazole], and pyrimidine analogues [flucytosine]). Fluconazole is the most widely used antifungal drug in sub-Saharan Africa, where cryptococcal meningitis is a major cause of death in patients infected with HIV. In this study, we found that exposure to fluconazole, even for short times (48 h) at subinhibitory concentrations, drove rapid adaptation of Cryptococcus neoformans serotype A strain H99 via the acquisition of different aneuploid chromosomes. These aneuploidies conferred heteroresistance to fluconazole. Importantly, most of the adaptors were cross-tolerant to flucytosine. Some of the aneuploid adaptors were not heteroresistant to fluconazole but were tolerant to amphotericin B. Thus, exposure to one antifungal drug class can promote adaptation to two antifungal drug classes, highlighting the plasticity of the C. neoformans genome and raising concerns about the rapid reduction in the range of treatment options for cryptococcal infections. IMPORTANCE Cryptococcosis is a globally distributed invasive fungal infection caused by infections with Cryptococcus neoformans or Cryptococcus gattii. Only three classes of therapeutic drugs are clinically available for treating cryptococcosis: polyenes (amphotericin B), azoles (fluconazole), and pyrimidine analogues (flucytosine). Fluconazole is the primary drug available in resource-limited countries. Aneuploidy is a genomic state due to the gain or loss of chromosomes. We found that C. neoformans rapidly adapted to fluconazole by acquiring diverse aneuploidies and that specific aneuploidies enabled improved growth of isolates susceptible (tolerance) to amphotericin B and/or cross-tolerance to both fluconazole and flucytosine. Therefore, aneuploidy is an underlying mechanism of drug tolerance that not only arises rapidly during growth in fluconazole but can also confer tolerance to other antifungal drugs without prior exposure to those drugs. Resistant isolates have high MICs, and all cells grow similarly in medium with the drug, while tolerant isolates test as susceptible and grow slowly at drug concentrations above the MIC. American Society for Microbiology 2021-09-29 /pmc/articles/PMC8557924/ /pubmed/34585947 http://dx.doi.org/10.1128/Spectrum.00723-21 Text en Copyright © 2021 Yang et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Yang, Feng
Gritsenko, Vladimir
Lu, Hui
Zhen, Cheng
Gao, Lu
Berman, Judith
Jiang, Yuan-ying
Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
title Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
title_full Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
title_fullStr Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
title_full_unstemmed Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
title_short Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
title_sort adaptation to fluconazole via aneuploidy enables cross-adaptation to amphotericin b and flucytosine in cryptococcus neoformans
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557924/
https://www.ncbi.nlm.nih.gov/pubmed/34585947
http://dx.doi.org/10.1128/Spectrum.00723-21
work_keys_str_mv AT yangfeng adaptationtofluconazoleviaaneuploidyenablescrossadaptationtoamphotericinbandflucytosineincryptococcusneoformans
AT gritsenkovladimir adaptationtofluconazoleviaaneuploidyenablescrossadaptationtoamphotericinbandflucytosineincryptococcusneoformans
AT luhui adaptationtofluconazoleviaaneuploidyenablescrossadaptationtoamphotericinbandflucytosineincryptococcusneoformans
AT zhencheng adaptationtofluconazoleviaaneuploidyenablescrossadaptationtoamphotericinbandflucytosineincryptococcusneoformans
AT gaolu adaptationtofluconazoleviaaneuploidyenablescrossadaptationtoamphotericinbandflucytosineincryptococcusneoformans
AT bermanjudith adaptationtofluconazoleviaaneuploidyenablescrossadaptationtoamphotericinbandflucytosineincryptococcusneoformans
AT jiangyuanying adaptationtofluconazoleviaaneuploidyenablescrossadaptationtoamphotericinbandflucytosineincryptococcusneoformans